SHARE TEXT
 
David R. Andes, MD close
Tvg6uXVvHQc
David R. Andes, MD
 

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

David R. Andes, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Andes’ clinical interests include general infectious diseases, transplant infectious diseases, mycology, antimicrobial pharmacokinetics and pharmacodynamics. 

Specialties

Infectious Diseases

Travel Medicine

Clinics

University Hospital
(608) 263-0946 | (800) 323-8942 | Map
University Hospital
(608) 890-6167 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Infectious Diseases
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School University of Missouri School of Medicine, Columbia, MO

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

The overriding themes of our research programs are to advance our understanding of antibacterial and antifungal activity and drug resistance, and to identify new antimicrobial drug treatment strategies and drug targets.


PubMed Articles
Lepak AJ Zhao M Liu Q Wang P Wang Y Bader JC Ambrose PG Andes DR Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against <i>S. aureus</i> and <i>S. pneumoniae</i>. Antimicrob Agents Chemother . 2018 Dec 17;
[PubMed ID: 30559140]
Koo H Andes DR Krysan DJ Candida-streptococcal interactions in biofilm-associated oral diseases. PLoS Pathog . 2018 Dec;14(12):e1007342
[PubMed ID: 30543717]
Kaindl T Andes D Engelhardt M Saulay M Larger P Groll AH Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother . 2018 Nov 21;
[PubMed ID: 30476108]
Andes DR Ghannoum MA Mukherjee PK Kovanda LL Lu Q Jones ME Santerre Henriksen A Lademacher C Hope WW Outcomes by Minimum Inhibitory Concentrations for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrob Agents Chemother . 2018 Oct 29;
[PubMed ID: 30373791]
Lepak AJ Zhao M Andes DR Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. Antimicrob Agents Chemother . 2018 Nov;62(11)
[PubMed ID: 30181375]
Sundermann AJ Clancy CJ Pasculle AW Liu G Cumbie RB Driscoll E Ayres A Donahue L Pergam SA Abbo L Andes DR Chandrasekar P Galdys AL Hanson KE Marr KA Mayer J Mehta S Morris MI Perfect J Revankar SG Smith B Swaminathan S Thompson GR 3rd Varghese M Vazquez J Whimbey E Wingard JR Nguyen MH How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. Clin Infect Dis . 2018 Oct 9;
[PubMed ID: 30299481]
Zarnowski R Sanchez H Covelli AS Dominguez E Jaromin A Bernhardt J Mitchell KF Heiss C Azadi P Mitchell A Andes DR Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis. PLoS Biol . 2018 Oct;16(10):e2006872
[PubMed ID: 30296253]
Andes D Has the optimal therapy for invasive candidiasis now been defined? Clin Infect Dis . 2018 Oct 5;
[PubMed ID: 30289475]
Zhao M Lepak AJ Marchillo K VanHecker J Andes DR <i>In Vivo</i> Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model. Antimicrob Agents Chemother . 2018 Sep;62(9)
[PubMed ID: 29987156]
Owens RC Jr Bulik CC Andes DR Pharmacokinetics-pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. Diagn Microbiol Infect Dis . 2018 Aug;91(4):371-382
[PubMed ID: 29776710]
Andes D Kovanda L Desai A Kitt T Zhao M Walsh TJ Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. Antimicrob Agents Chemother . 2018 Jul;62(7)
[PubMed ID: 29735569]
Van Dijck P Sjollema J Cammue BP Lagrou K Berman J d'Enfert C Andes DR Arendrup MC Brakhage AA Calderone R Cantón E Coenye T Cos P Cowen LE Edgerton M Espinel-Ingroff A Filler SG Ghannoum M Gow NAR Haas H Jabra-Rizk MA Johnson EM Lockhart SR Lopez-Ribot JL Maertens J Munro CA Nett JE Nobile CJ Pfaller MA Ramage G Sanglard D Sanguinetti M Spriet I Verweij PE Warris A Wauters J Yeaman MR Zaat SAJ Thevissen K Methodologies for <i>in vitro</i> and <i>in vivo</i> evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microb Cell . 2018 Jun 14;5(7):300-326
[PubMed ID: 29992128]
Kim D Liu Y Benhamou RI Sanchez H Simón-Soro � Li Y Hwang G Fridman M Andes DR Koo H Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm. ISME J . 2018 Jun;12(6):1427-1442
[PubMed ID: 29670217]
Jaromin A Zarnowski R Piętka-Ottlik M Andes DR Gubernator J Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced antifungal activity. Nanomedicine (Lond) . 2018 May;13(10):1139-1155
[PubMed ID: 29873597]
Dominguez E Zarnowski R Sanchez H Covelli AS Westler WM Azadi P Nett J Mitchell AP Andes DR Conservation and Divergence in the <i>Candida</i> Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. MBio . 2018 Apr 3;9(2)
[PubMed ID: 29615504]
Park JH Craig W Marchillo K Huang DB Andes DR Identification of the <i>In Vivo</i> Pharmacokinetics and Pharmacodynamic Driver of Iclaprim. Antimicrob Agents Chemother . 2018 Apr;62(4)
[PubMed ID: 29378717]
Zhao M Lepak AJ VanScoy B Bader JC Marchillo K Vanhecker J Ambrose PG Andes DR <i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. Antimicrob Agents Chemother . 2018 Apr;62(4)
[PubMed ID: 29378706]
Lepak AJ Zhao M VanScoy B Ambrose PG Andes DR Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. Antimicrob Agents Chemother . 2018 Feb;62(2)
[PubMed ID: 29203480]
Bader JC Bhavnani SM Andes DR Ambrose PG We can do better: a fresh look at echinocandin dosing. J Antimicrob Chemother . 2018 Jan 1;73(suppl_1):i44-i50
[PubMed ID: 29304211]
Srivastava A Sircaik S Husain F Thomas E Ror S Rastogi S Alim D Bapat P Andes DR Nobile CJ Panwar SL Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans. Cell Microbiol . 2017 Dec;19(12)
[PubMed ID: 28745020]